Oncology
Conference Coverage
Immune checkpoint inhibition in SCLC: Modest outcomes, many questions
Immune checkpoint inhibitors have activity in SCLC, but achieving more durable disease control and better survival requires greater understanding...
Conference Coverage
KRAS-mutation colon, rectal cancers have distinct survival profiles
Opinion
USPSTF recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer
They recommend using screening tools focusing on family history that primary care physicians can utilize to determine who should be referred for...
Conference Coverage
Patients have good recall on lung cancer screening scan benefits, not risks
NEW ORLEANS – Results suggest need for ongoing patient education beyond the initial shared decision-making encounter.
News
How to overcome barriers to exercise for cancer patients
Consider the assessment of physical activity a vital sign for cancer patients and survivors.
News
Trastuzumab benefit lasts long-term in HER2+ breast cancer
The benefit of trastuzumab was greater among patients with HR+ disease than those with HR– disease until the 5-year timepoint, after which HR...
Conference Coverage
Nivolumab boosts overall survival in HCC
BARCELONA – Nivolumab led to clinically meaningful, but not statistically significant, improvement in OS and ORR vs. sorafenib for first-line...
News
New practice guideline: CRC screening isn’t necessary for low-risk patients aged 50-75 years
For individuals aged 50-79 with no symptoms and an estimated 15-year CRC risk below 3%, no screening is recommended by BMJ Rapid Recommendations...
Article
Comparing Artificial Intelligence Platforms for Histopathologic Cancer Diagnosis
Two machine learning platforms were successfully used to provide diagnostic guidance in the differentiation between common cancer conditions in...
Latest News
Gene recurrence score helps predict successful combination therapy for early breast cancer
Women with a high recurrence score on a 21-gene breast cancer assay fared better with chemoendocrine therapy than expected with endocrine therapy...
